Skip to content
DataLookout
Menu

NCT07951281

Performance of Lumetry for Arterial Carbon Dioxide (paCO2) Assessment and Chronic Obstructive Pulmonary Disease (COPD) Screening

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and End-Tidal Carbon Dioxide (petCO2)
Timeframe: Day 1 (single study visit)
Sensitivity of the lumetry COPD Screening Result
Timeframe: Day 1 (single study visit)
Specificity of the lumetry COPD Screening Result
Timeframe: Day 1 (single study visit)

Secondary (3)

Standard Deviation of the Differences Between lumetry-Estimated paCO2 and Blood Gas paCO2
Percentage of lumetry paCO2 Estimates Within 8 mmHg of Blood Gas paCO2
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and Transcutaneous Carbon Dioxide (tcPCO2)

Arms and interventions

Participants With and Without COPDExperimental

Adults with chronic obstructive pulmonary disease (COPD), stratified by severity (50 GOLD I/II, 50 GOLD III, 50 GOLD IV), and 150 adults without known lung function pathologies. All participants perform a single 60-second lumetry measurement of normal resting breathing, followed by forced spirometry. Participants with COPD additionally undergo arterialized capillary blood gas analysis, with a subgroup of 50 participants with COPD (GOLD III and IV) additionally undergoing transcutaneous carbon dioxide monitoring.

Devices: lumetry

Diagnostic tests: Arterialized Capillary Blood Gas Analysis, Transcutaneous Carbon Dioxide Monitoring, Forced Spirometry

Sites

1 site in 1 country

  • Klinik Floridsdorf, Department of Respiratory and Critical Care MedicineVienna, State of Vienna, Austria